Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
Alaunos Therapeutics (TCRT) announced their Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations in solid tumors is actively enrolling patients. The company has appointed Abhishek Srivastava, Ph.D., as VP, Technical Operations, and extended its collaboration with the National Cancer Institute until 2025. Financially, Alaunos reported a 62% decrease in operating cash burn for Q2 2022 to $8.2 million, and a net loss of $9.9 million or $(0.05) per share. The company expects its cash runway to fund operations until Q2 2023.
- Operating cash burn decreased by 62% to $8.2 million in Q2 2022.
- Net loss reduced to $9.9 million, down from $22.7 million in Q2 2021.
- Strengthened manufacturing capabilities with the appointment of Abhishek Srivastava as VP, Technical Operations.
- Net loss of $9.9 million indicates ongoing financial challenges.
- Research and development expenses decreased 56%, suggesting potential setbacks in program advancements.
- Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with second dose level
- Extended Cooperative Research and Development Agreement for development of personalized TCR-T cell therapies with the National Cancer Institute of the National Institute of Health to 2025
- Appointed Abhishek Srivastava, Ph.D. as VP, Technical Operations
- Advancing multi-pronged strategy to bolster in-house manufacturing capacity
- Operating cash burn in 2Q 2022 was
$8.2 million , a decrease of62% from the same period last year
HOUSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the second quarter ended June 30, 2022.
“The team has made tremendous progress building a strong operational, manufacturing, and clinical foundation over the past year. Our TCR-T Library Phase 1/2 trial is actively enrolling, and I am pleased to announce that we are moving ahead at the second dose level,” commented Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. “The recent hiring of Abhi Srivastava as our VP of Technical Operations strengthens our manufacturing capabilities as we work to increase our manufacturing capacity to support future clinical expansion. In addition to our internal efforts, we were privileged to extend our collaboration with Dr. Rosenberg and the National Cancer Institute to develop personalized cancer therapies using our novel TCR-T cell platform. We believe that Alaunos is poised for long term success. We look forward to presenting early data from our Phase 1/2 trial in the third quarter and remain committed to improving the lives of cancer patients with solid tumors.”
Recent Developments and Upcoming Milestones
TCR-T Library Phase 1/2 Trial: The Company continues to advance its TCR-T Library Phase 1/2 trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications. In May 2022, the Company announced dosing of the first patient in the trial. The patient has non-small cell lung cancer and was treated with TCR-T cells targeting a KRAS G12D mutation. Following a safety review by the safety review committee at the MD Anderson Cancer Center, the Company is now moving ahead at the second dose level. The main study objectives are to define the maximum tolerated dose, recommended Phase 2 dose and safety profile. The Company expects to present early data in the third quarter of 2022. Additional information about the trial is available at www.clinicaltrials.gov using the identifier: NCT05194735.
Extended Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for Development of Personalized TCR-T Cell Therapies: In June 2022, the Company announced that it had extended its CRADA with the NCI, regarding the Company’s Sleeping Beauty technology, through January 2025. Under the CRADA, the NCI will work to generate proof of concept data utilizing the Company’s proprietary non-viral Sleeping Beauty technology for personalized TCR-T cell therapies. In this approach, T-cell receptors (TCRs) that react to the patient’s tumor are identified from the patient and used in an effort to generate a fully autologous, personalized TCR-T cell therapy. Research conducted under the CRADA will be led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI's Center for Cancer Research.
cGMP Manufacturing Facility: The Company’s state-of-the-art good manufacturing practice (cGMP) TCR manufacturing facility is fully operational for the manufacture and release of clinical product. The Company is executing on a multi-pronged strategy to expand its manufacturing capabilities. Alaunos is implementing new standard operating procedures that allow for simultaneous production of multiple products, including further optimizing the manufacturing process by introducing cryopreserved cell products. In addition, the Company is hiring additional staff to support increased manufacturing and is evaluating additional strategies including physically expanding its cGMP footprint.
Corporate Updates: In August 2022, Abhishek Srivastava, Ph.D. was appointed Vice President, Technical Operations. Dr. Srivastava joined Alaunos from Athenex, where he was Vice President, Cell Therapy Development.
Second Quarter Ended June 30, 2022 Financial Results
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and administrative expenses were
Net Loss: Net loss was
Cash and Cash Equivalents: As of June 30, 2022, Alaunos had approximately
Conference Call and Webcast
Alaunos will host a conference call and webcast today, August 15, 2022, at 8:30am ET. Participants may access the live webcast using the link here or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.
About Alaunos Therapeutics
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer technology and its TCR library targeting shared tumor-specific hotspot mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute. For more information, please visit www.alaunos.com.
Forward-Looking Statements Disclaimer
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” “believes” or other words or terms of similar meaning. These statements include, but are not limited to, statements regarding the Company's business and strategic plans, the anticipated outcome of preclinical and clinical studies by the Company or its third-party collaborators, the Company's cash runway, the Company’s manufacturing capabilities, and the timing of the Company's research and development programs, including the anticipated dates for enrolling and dosing patients in and the expected timing for announcing preclinical data and results from the Company’s clinical trials. Although the management team of Alaunos believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Alaunos, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, changes in the Company’s operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Alaunos’ product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Alaunos’ intellectual property rights; and competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Alaunos, including those risks and uncertainties listed in the most recent periodic report filed by Alaunos with the Securities and Exchange Commission. Alaunos is providing this information as of the date of this press release, and Alaunos does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.
Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com
Alaunos Therapeutics, Inc
Statement of Operations
(In thousands except per share data)
| For the Three Months Ended June 30 (Unaudited) | ||||||
| 2022 | 2021 | |||||
| Operating Expenses: | ||||||
| Research and development | $ | 5,937 | $ | 13,570 | ||
| General and administrative | 3,429 | 9,069 | ||||
| Gain on lease modification | (133 | ) | — | |||
| Total operating expenses | 9,233 | 22,639 | ||||
| Loss from operations | (9,233 | ) | (22,639 | ) | ||
| Interest expense | (740 | ) | — | |||
| Other income (expense), net | 41 | (31 | ) | |||
| Net loss | (9,932 | ) | (22,670 | ) | ||
| Net loss applicable to common stockholders | (9,932 | ) | (22,670 | ) | ||
| Basic and diluted net loss per share | $ | (0.05 | ) | $ | (0.11 | ) |
| Weighted average number of common shares outstanding, basic and diluted | 214,998,893 | 214,426,406 | ||||
Alaunos Therapeutics, Inc
Selected Balance Sheet Data
(In thousands)
| (unaudited) | (audited) | |||
| June 30, 2022 | December 31, 2021 | |||
| Cash and cash equivalents | $ | 60,011 | $ | 76,054 |
| Working capital | $ | 34,586 | $ | 62,790 |
| Total assets | $ | 73,931 | $ | 94,865 |
| Total stockholders’ equity | $ | 40,180 | $ | 58,057 |
FAQ
What are the recent developments for Alaunos Therapeutics (TCRT) in their clinical trials?
How much was Alaunos Therapeutics' cash burn in Q2 2022?
What is the financial outlook for Alaunos Therapeutics (TCRT) after their latest earnings report?
What was Alaunos Therapeutics' net loss for Q2 2022?
